These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38859589)

  • 1. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy.
    Gondaliya P; Sayyed AA; Yan IK; Driscoll J; Ziemer A; Patel T
    Mol Ther; 2024 Aug; 32(8):2762-2777. PubMed ID: 38859589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M
    Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
    Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
    Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
    Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
    Yoo B; Jordan VC; Sheedy P; Billig AM; Ross A; Pantazopoulos P; Medarova Z
    Sci Rep; 2019 Mar; 9(1):4712. PubMed ID: 30886310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
    Wathikthinnakon M; Luangwattananun P; Sawasdee N; Chiawpanit C; Lee VS; Nimmanpipug P; Tragoolpua Y; Rotarayanont S; Sangsuwannukul T; Phanthaphol N; Wutti-In Y; Somboonpatarakun C; Chieochansin T; Junking M; Sujjitjoon J; Yenchitsomanus PT; Panya A
    Sci Rep; 2022 Apr; 12(1):6154. PubMed ID: 35418130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
    Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
    J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
    Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
    PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
    Koido S; Kan S; Yoshida K; Yoshizaki S; Takakura K; Namiki Y; Tsukinaga S; Odahara S; Kajihara M; Okamoto M; Ito M; Yusa S; Gong J; Sugiyama H; Ohkusa T; Homma S; Tajiri H
    Anticancer Res; 2014 Nov; 34(11):6353-61. PubMed ID: 25368235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
    Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
    Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
    Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
    Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
    Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
    Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
    Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
    Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
    Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.